As reported last week at CNN, FDA has approved a new drug, Azilect (also called rasagiline), which helps block the breakdown of a chemical that contributes to problems with movement and coordination (dopamine) that marks Parkinson’s disease.
Azilect has been approved by the USFDA for use as an initial single-drug therapy for early Parkinson's disease, and as an additional to levodopa (standard treatment for Parkinson’s) in more advanced patients.
Azilect is made by Teva Pharmaceutical Industries of Israel which also has the potential to cause involuntary movements, hallucinations and lowered blood pressure, according to the FDA.
Read the full report at CNN Health.
Comment Preview